top of page

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors



Hackensack University Medical Center, Hackensack, New Jersey, United States|Prisma Health Cancer Institute Faris, Greenville, South Carolina, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Universitair Ziekenhuis Brussel, Brussels, Belgium|Institut Jules Bordet, Brussels, Belgium|Universitair Ziekenhuis Antwerpen (Uza), Edegem, Belgium|Ghent University Hospital, Ghent, Belgium|Universitaire Ziekenhuis Leuven - Gasthuisberg, Leuven, Belgium|Rigshospitalet Uni of Hospital of Copenhagen, Kobenhavn, Denmark|Helsinki University Central Hospital, Helsinki, Finland|Docrates Cancer Center, Helsinki, Finland|Tampere University Hospital, Tampere, Finland|Turku University Hospital, Turku, Finland|Haukeland University Hospital, Bergen, Norway|Oslo Universitetssykehus, Oslo, Norway|Sahlgrenska University Hospital, Goteborg, Sweden|Karolinska University Hospital Solna, Solna, Sweden|Uppsala Universitet - Akademiska Sjukhuset, Uppsala, Sweden|Western General Hospital, Edinburgh, United Kingdom|St James University Hospital, Leeds, United Kingdom|Guys and St Thomas Nhs Foundation Trust, London, United Kingdom|The Royal Marsden Hospital Nhs Trust London, London, United Kingdom|Imperial College Healthcare Nhs Trust - Hammersmith Hospital, London, United Kingdom|Freeman Hospital Newcastle Upon Tyne Foundation Nhs Trust, Newcastle Upon Tyne, United Kingdom


Drug: INCB099318

The study consists of 2 parts. Part 1 is a dose-escalation design to identify the maximum tolerated dose and/or pharmacologically active dose for INCB099318. Part 2 is an expansion at 1 or more dose levels to further explore safety, preliminary efficacy, pharmacoketics, and pharmacodynamic effects.


bottom of page